Thyrocare Technologies Limited (THYROCARE.BO)
Thyrocare Technologies Limited operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Navi Mumbai, MA, IN. The stock last traded at $623.80, up 2.86% on the session, giving a market capitalisation of $99.26B. Its beta of 0.47 implies it has historically moved less than the broad market.
Thyrocare Technologies Limited, an Indian enterprise founded in 1996 and based in Navi Mumbai, operates as a subsidiary of Docon Technologies Private Limited. The company provides a comprehensive suite of diagnostic testing services to individuals, clinics, and medical facilities throughout India. Its operations are structured into three distinct divisions: Diagnostic Testing Services, Imaging Services, and Other Services. Thyrocare focuses on conducting a broad spectrum of medical diagnostic analyses and test bundles aimed at the timely detection and effective management of various health conditions and diseases. These encompass thyroid dysfunctions, growth disorders, metabolic imbalances, autoimmune conditions, diabetes, anaemia, cardiovascular issues, infertility, COVID-19, and a range of infectious diseases. A prominent offering is the Aarogyam brand, which delivers extensive wellness and proactive health screening packages. In addition to its testing services, the company supplies medical devices like glucometers and glucostrips under the Sugarscan label, along with other consumables and radiopharmaceuticals.
Thyrocare Technologies Limited is most often compared with the following Healthcare names: